DiaSorin (OTCMKTS:DSRLF) Reaches New 52-Week Low - Time to Sell?

Key Points

• DiaSorin S.p.A. hit a new 52-week low, trading as low as $94.25, down from a previous close of $100.00.
• Analysts from Royal Bank Of Canada and Morgan Stanley have upgraded DiaSorin’s stock rating to "outperform" and "overweight", respectively, indicating growing investor confidence.
• The stock has a Moderate Buy average rating among analysts, with two giving it a Buy rating and one a Hold rating.

DiaSorin S.p.A. (OTCMKTS:DSRLF - Get Free Report) hit a new 52-week low on Saturday . The stock traded as low as $94.25 and last traded at $94.25, with a volume of 1 shares. The stock had previously closed at $100.00.

Analysts Set New Price Targets

Several brokerages have weighed in on DSRLF. Royal Bank Of Canada raised DiaSorin to an "outperform" rating in a report on Thursday, August 14th. Morgan Stanley raised DiaSorin from an "underweight" rating to an "overweight" rating in a report on Tuesday, August 26th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy".

DiaSorin Price Performance

The stock has a 50 day moving average price of $104.95 and a 200-day moving average price of $106.78.

About DiaSorin

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.